WHO ICTRP trial
Efficacy and Safety Comparison of Cofrogliptin Add-on versus Metformin…
ChiCTR2400090646 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2400090646 |
|---|---|
| Public title | Efficacy and Safety Comparison of Cofrogliptin Add-on versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled with SGLT-2 Inhibitors plus Low-Dose Metformin:A Multicenter, Open-Label, Randomized Controlled Trial |
| Scientific title | The Efficacy and Safety of biweekly Cofrogliptin Add-on versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled with SGLT-2 Inhibitors plus Low-Dose Metformin:A Multicenter, Open-Label, Randomized Controlled Trial |
| Primary sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Type 2 diabetes |
| Interventions | cofrogliptin add-on group:The cofrogliptin add-on group will continue their existing SGLT2i plus metformin regimen and dosing, with the add-on of cofrogliptin over 24 weeks of triple combined therapy.;Metformin dose escalation group:The… |
| Registration date | Oct 10, 2024 |
| Target size | cofrogliptin add-on group:40;Metformin dose escalation group:40 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: